Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haploidentical HSCT with post-transplant cyclophosphamide plus short-term methotrexate for thalassemia major
ChiCTR1800017969Phase 3Recruiting
- Sponsor
- Xiangya Hospital, Central South University
- Start
- Sep 2018
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of cyclophosphamide and methotrexate in beta thalassemia major, sponsored by Xiangya Hospital, Central South University. Primary endpoints: Cumulative incidence of acute graft-versus-host disease, Incidence of regimen-related mortality and 1 more. Started Sep 2018; status: recruiting.
02
Drugs
cyclophosphamidemethotrexate
03
Conditions
beta thalassemia major
Beyond the preview
Go deeper on ChiCTR1800017969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017969.